STUDY HYPOTHESIS: 3,4-Diaminopyridine (3,4-DAP) may reverse the hemodynamic effects of severe verapamil toxicity. DESIGN: A nonblinded acute animal preparation. INTERVENTIONS: Eighteen chloralose-anesthetized and instrumented swine were poisoned with verapamil at 10 mg/kg/hr for five minutes and then 5 mg/kg/hr until a systolic blood pressure of 55 mm Hg was achieved. Heart rate, lead II ECG, mean arterial pressure, left ventricular dP/dT max, and cardiac index were monitored. Nine control animals received 0.2 mL/kg/min infusion of normal saline, and nine treatment animals received similar volumes of 1 mg/kg/min 3,4-DAP until systolic blood pressure reached 100 mm Hg, an elapsed time of 30 minutes, or death. RESULTS: Verapamil toxicity was produced in all animals following an average dose of 1.38 +/- 0.44 mg/kg verapamil, and resulted in diminished mean arterial pressure, dP/dT max, cardiac index, and heart rate to average values of 47%, 32%, 46%, and 88% of baseline values, respectively. Transient atrioventricular dissociation was noted in only 22% of cases. 3,4-DAP treatment (with an average dose of 14 +/- 5.6 mg/kg) resulted in significant increases in mean arterial pressure, dP/dT max, cardiac index, and heart rate to 136%, 298%, 149%, and 158% of baseline values, respectively. Mortality was unchanged (22% in both groups). 3,4-DAP treatment was complicated by muscle twitching, tachycardia (rate of more than 180) and hypertension (diastolic blood pressure of more than 110 mm Hg) each in 44% of cases. CONCLUSION: Although 3,4-DAP reversed the hypotensive and negative inotropic effects of verapamil toxicity, it failed to improve survival and resulted in several complications including muscle twitching, tachycardia, and hypertension.
STUDY HYPOTHESIS: 3,4-Diaminopyridine (3,4-DAP) may reverse the hemodynamic effects of severe verapamiltoxicity. DESIGN: A nonblinded acute animal preparation. INTERVENTIONS: Eighteen chloralose-anesthetized and instrumented swine were poisoned with verapamil at 10 mg/kg/hr for five minutes and then 5 mg/kg/hr until a systolic blood pressure of 55 mm Hg was achieved. Heart rate, lead II ECG, mean arterial pressure, left ventricular dP/dT max, and cardiac index were monitored. Nine control animals received 0.2 mL/kg/min infusion of normal saline, and nine treatment animals received similar volumes of 1 mg/kg/min 3,4-DAP until systolic blood pressure reached 100 mm Hg, an elapsed time of 30 minutes, or death. RESULTS:Verapamiltoxicity was produced in all animals following an average dose of 1.38 +/- 0.44 mg/kg verapamil, and resulted in diminished mean arterial pressure, dP/dT max, cardiac index, and heart rate to average values of 47%, 32%, 46%, and 88% of baseline values, respectively. Transient atrioventricular dissociation was noted in only 22% of cases. 3,4-DAP treatment (with an average dose of 14 +/- 5.6 mg/kg) resulted in significant increases in mean arterial pressure, dP/dT max, cardiac index, and heart rate to 136%, 298%, 149%, and 158% of baseline values, respectively. Mortality was unchanged (22% in both groups). 3,4-DAP treatment was complicated by muscle twitching, tachycardia (rate of more than 180) and hypertension (diastolic blood pressure of more than 110 mm Hg) each in 44% of cases. CONCLUSION: Although 3,4-DAP reversed the hypotensive and negative inotropic effects of verapamiltoxicity, it failed to improve survival and resulted in several complications including muscle twitching, tachycardia, and hypertension.
Authors: Joseph S Zakhari; Isao Kinoyama; Mark S Hixon; Antonia Di Mola; Daniel Globisch; Kim D Janda Journal: Bioorg Med Chem Date: 2011-09-14 Impact factor: 3.641
Authors: Alexander V Mayorov; Bert Willis; Antonia Di Mola; Derek Adler; Jennifer Borgia; Olin Jackson; Jie Wang; Yongyi Luo; Lei Tang; Richard J Knapp; Chandra Natarajan; Michael C Goodnough; Noam Zilberberg; Lance L Simpson; Kim D Janda Journal: ACS Chem Biol Date: 2010-10-22 Impact factor: 5.100
Authors: J Dave Barry; Dave Durkovich; Lee Cantrell; William Richardson; Tri Tong; Steve Offerman; Richard F Clark; David A Tanen; Saralyn Williams Journal: J Med Toxicol Date: 2005-12
Authors: M St-Onge; P-A Dubé; S Gosselin; C Guimont; J Godwin; P M Archambault; J-M Chauny; A J Frenette; M Darveau; N Le Sage; J Poitras; J Provencher; D N Juurlink; R Blais Journal: Clin Toxicol (Phila) Date: 2014-10-06 Impact factor: 4.467